Integrated Wealth Concepts LLC Buys 41,564 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Integrated Wealth Concepts LLC increased its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 16.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 288,101 shares of the company's stock after buying an additional 41,564 shares during the period. Integrated Wealth Concepts LLC's holdings in Roivant Sciences were worth $3,408,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of ROIV. Barclays PLC lifted its stake in shares of Roivant Sciences by 19.7% in the 3rd quarter. Barclays PLC now owns 459,521 shares of the company's stock valued at $5,302,000 after purchasing an additional 75,609 shares during the period. Virtu Financial LLC acquired a new position in shares of Roivant Sciences during the 3rd quarter worth about $207,000. Te Ahumairangi Investment Management Ltd raised its position in shares of Roivant Sciences by 19.9% in the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 201,612 shares of the company's stock valued at $2,313,000 after acquiring an additional 33,467 shares during the period. Tyro Capital Management LLC raised its holdings in Roivant Sciences by 0.6% in the third quarter. Tyro Capital Management LLC now owns 1,754,976 shares of the company's stock worth $20,252,000 after purchasing an additional 10,649 shares during the period. Finally, Retirement Systems of Alabama lifted its holdings in Roivant Sciences by 26.9% during the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company's stock worth $6,116,000 after acquiring an additional 112,286 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Roivant Sciences

In other news, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the sale, the chief accounting officer now owns 163,264 shares of the company's stock, valued at approximately $1,702,843.52. This trade represents a 58.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Eric Venker sold 218,041 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the completion of the transaction, the chief operating officer now owns 896,869 shares in the company, valued at $9,345,374.98. This trade represents a 19.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,395,541 shares of company stock worth $14,922,538 over the last ninety days. Insiders own 7.90% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Monday, April 21st.

Roivant Sciences Trading Down 0.3 %

Shares of Roivant Sciences stock traded down $0.04 during trading hours on Thursday, reaching $11.58. 8,592,628 shares of the company's stock were exchanged, compared to its average volume of 5,501,811. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $13.06. The stock has a market cap of $8.26 billion, a P/E ratio of -77.19 and a beta of 1.25. The company has a 50 day moving average of $10.38 and a two-hundred day moving average of $11.14.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.